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Abstract Modafinil is a non-amphetamine wakefulness-
promoting agent used for the treatment of various sleep
disorders characterized by excessive daytime sleepiness.
There is little information in the medical literature with
respect to supratherapeutic doses of this medication. We
performed a retrospective review of the California Poison
Control System database for all cases of single-substance
ingestion of modafinil with follow-up to a known outcome
for the time period 1998–2008. Data collected included age,
gender, dose ingested, clinical effects, and medical out-
come. There were a total of 87 patients, 53 (61%) of which
were female. Patient ages ranged from 1.25 to 72 years with
a mean of 30 years; 17 (20%) patients were aged 6 years or
less. Thirty-three (38%) were intentional overdoses. Most
commonly reported effects were tachycardia (n=23),
agitation (n=14), anxiety (n=11), headache (n=8), hyper-
tension (n=6), dystonia/tremor (n=6), and dizziness (n=5).
Forty-nine patients (56%) were managed at home, and 38
(44%) were managed in a healthcare setting. Therapies
administered included activated charcoal (n=8), benzodiaze-
pines (n=7), antihistamines (n=2), intravenous fluids (n=2),
haloperidol (n=2), and beta-blockers (n=1). Effects were
classified as none (n=22), minor (n=54), and moderate
(n=11). No major effects and no deaths occurred. Effects of
modafinil overdose appear to be mild in most cases, with
tachycardia and CNS symptoms predominating. Clinically
significant effects requiring treatment occurred in a small
number of patients.
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Introduction
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide) is a
unique non-amphetamine wakefulness-promoting agent that
was first marketed in France in the early 1990s for the
treatment of excessive somnolence in patients with narco-
lepsy. It was subsequently approved in the USA in 1998
under the brand name Provigil® and is used for the
treatment of various sleep disorders characterized by
excessive sleepiness, including narcolepsy, obstructive
sleep apnea, and shift work sleep disorder. It has steadily
gained popularity among prescribers due to its wakefulness-
promoting efficacy, presumed lower potential for abuse,
and lack of peripheral sympathomimetic effects commonly
observed with amphetamine stimulants. As a result, it has
been studied and used off-label to treat sedation and fatigue
in neurological and medical conditions including multiple
sclerosis [1], Parkinson’s disease [2], HIV infection [3],
cancer [4], and fibromyalgia [5]. It has also shown promise
in the treatment of cocaine dependence and withdrawal
[6–8], alcoholic organic brain disorder [9, 10], and in
augmentation of antidepressant regimens [11].
Modafinil appears to have a complex mechanism of
action that is not completely understood. It is known to cause
an increase in extracellular concentrations of dopamine,
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cause a decrease in extracellular gamma-aminobutyric acid
intheneocortex[12]. Ithasbeenshowntobindtoandinhibit
the dopamine transporter and norepinephrine transporter at
clinically relevant doses, which may be responsible in part
for its therapeutic effects [13]. Unlike amphetamines,
modafinil has no effect on spontaneous dopamine release
or turnover and lacks peripheral sympathomimetic effects
[12, 14, 15].
Little information on supratherapeutic dosing of modafinil
exists in the current medical literature. Two small case series
have been published in abstract form [16, 17], and a recent
review of data from 11 states was published by Spiller et al.
[18]. During clinical trials, intentional acute overdoses as
high as 4,500 mg were reported, with insomnia, tachycardia,
agitation, and anxiety being the only side effects reported; no
life-threatening toxicity occurred, and to date, no fatal
overdoses have occurred involving modafinil alone [19].
We performed a retrospective chart review of modafinil
exposures reported to the California Poison Control System
overan11-yearperiod.Ouraiminthisstudywastocharacterize
the clinical effects and toxicity associated with overdose of
modafinil in the hope of improving treatment guidelines and
recommendations for patients with modafinil ingestion.
Methods
The University of California–San Diego Institutional
Review Board approved this retrospective cohort study. A
retrospective chart review of the California Poison Control
System (CPCS) electronic database (Visual Dotlab) for cases
between the years 1998 and 2008 was performed. Search
codes included the terms “modafinil” and “Provigil.” Cases
were assessed by the principal and assistant investigators
only after removal of all patient identifiers. Inclusion criteria
included patients of any age with single substance exposure
to modafinil and follow-up to a known outcome (this cohort
included patients exposed to modafinil who were described
in abstract form in [16, 17]). Exclusion criteria were history
of any co-ingestants and inability to follow the patient to a
known outcome.
Data collected included date of occurrence, age, gender,
weight (where available), dose ingested by history (or, in the
case of a child, pill count or events witnessed by a parent),
whetherexposurewasintentionalorunintentional,symptoms,
duration of clinical effects, site of exposure, management site,
treatment, length of hospital stay, and clinical outcome.
Among intentional exposures, “abuse” was defined as use of
the medication for purported psychotropic effects, while
“misuse” was defined as use of the medication for its known
stimulatingeffectsfornon-FDA-approvedindications (e.g.,to
facilitate studying). Tachycardia was defined as a heart rate
>100 bpm, and hypertension was defined as a systolic blood
pressure >140 mmHg or diastolic blood pressure >90 mmHg.
Outcomes were coded as “no effect,”“ minor effect,”
“moderate effect,”“ major effect,” or “death” according to
the criteria set forth by the American Association of Poison
Control Centers [20]. All data abstracted were transcribed
into a standardized Microsoft Excel 2008 for Mac (Micro-
soft, Redmond, WA) spreadsheet.
Results
Atotalof257casesofmodafinilingestionwerereportedtothe
CPCS between 1998 and 2008. Eighteen cases were excluded
because of confirmed non-exposure (e.g., all pills were later
accounted for), 43 were excluded due to lack offollow-up to a
known outcome, 108 were excluded due to reported co-
ingestants, and one was a non-human (canine) exposure. This
left 87 cases that met inclusion criteria (see Fig. 1).
Fifty-three patients (60.9%) were female. Patient ages
ranged from 1.25 to 72 years with a mean of 29.9 years.
Seventeen patients (19.5%) were 6 years of age or less.
257 modafinil exposures identified
170 cases excluded:
  Confirmed nonexposure (n=18)
  No follow up to known outcome (n=43)
  Coingestion of other substance (n=108)
  Non-human exposure (n=1)
87 cases met inclusion criteria
Fig. 1 Flow diagram of identified modafinil exposures
Table 1 Exposure management sites
Exposure management site Number of patients (%)
On-site (e.g., home) 49 (56.3)
Emergency department 33 (37.9)
Critical Care Unit 4 (4.6)
Physician’s office 1 (1.1)
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modafinil. Of these, mean and median doses ingested were
939 and 400 mg, respectively, with a range of 25–16,100 mg.
Exposure management sites are listed in Table 1; the majority
of patients (56.3%) were managed in a non-healthcare
facility setting.
Effectswereclassifiedasnoeffect(n=22), minor (n=54),
and moderate (n=11). No major effects and no deaths were
documented. Table 2 shows a summary of medical out-
comes by ingested dose. Therapies administered included
activated charcoal (n=8), benzodiazepines (n=7), antihist-
amines (n=2), intravenous fluids (n=2), haloperidol (n=2),
and beta-blockers (n=1).
Clinical effects are summarized in Table 3. The most
frequently reported effect was tachycardia, which occurred
in 23 patients (26.4%) and ranged from 101 to 168 bpm.
Hypertension occurred in six patients (6.9%). No cardiac
dysrhythmias were reported. There was one report of chest
pain in a 65-year-old male who inadvertently took 800 mg
of modafinil after mistaking it for acetaminophen; vital
signs revealed a heart rate of 64 bpm and blood pressure of
137/78 mmHg, and troponin measurements were negative.
Neurologic effects following excessive modafinil inges-
tion also occurred frequently and manifested primarily as
agitation, anxiety, and headache. One 37-year-old female
accidentally ingested 1,600 mg of modafinilandpresented to
an ED with agitation, visual hallucinations, and marked
orofacial dyskinesia. She was administered lorazepam and
diphenhydramine without significant improvement. She was
noted to have a heart rate of 115 bpm and blood pressure of
138/73 mmHg. She was admitted to the intensive care unit
where she experienced prolonged dysarthria. She remained
tachycardic for 13 h and was ultimately discharged from the
hospital 20 h post-ingestion without sequelae.
Thirty-three exposures (37.9%) were intentional. Of these,
five (5.7%) were due to misuse, while six (6.9%) were due to
abuse. Ingestions were unintentional in 54 (62.1%) cases. Of
these, 19 were instances where a patient had inadvertently
taken a double dose of their medication. Eighteen of these
patients had no significant effects; the one symptomatic
patient was a 24-year-old female who accidentally ingested
400 mg instead of her usual single 200 mg tablet and who
presentedtoanEDwitha heart rate of168 and blood pressure
of 168/131 mmHg. She was treated with labetalol and was
discharged home after a period of observation.
Discussion
Single-agent exposures to modafinil appear to occur
infrequently. In this case series, effects in overdose were
usually minor, and significant toxicity occurred only rarely.
Specific treatment was required in a minority of patients.
Our results are similar to those of the recent study by
Spiller et al. [18] which examined data from poison control
centers of 11 states. As would be expected, increasing mean
and median dosages were associated with more significant
clinical effects.
No effect Minor effect Moderate effect
All patients (n=87) 22 (25.3%) 54 (62.1%) 11 (12.6%)
Patients with known dose (n=81) 22 (27.2%) 50 (61.7%) 9 (11.1%)
Dose range (mg) 50–1200 25–16100 400–8,000
Mean dose (mg) 411 995 1,922
Median dose (mg) 250 400 1,200
All patients ≤6 years old (n=17) 11 (64.7%) 6 (35.3%) –
Patients ≤6 years old with known dose (n=16) 11 (68.8%) 5 (31.3%) –
Dose range (mg) 50–500 25–1,000 –
Mean dose (mg) 186 275 –
Median dose (mg) 100 100 –
Table 2 Summary of medical
outcome by dose of modafinil
ingested
Table 3 Clinical effects
Clinical effect Number of patients (%)
Tachycardia 23 (26.4)
Agitation 14 (16.1)
Anxiety 11 (12.6)
Headache 8 (9.2)
Hypertension 6 (6.9)
Dystonia/tremor 6 (6.9)
Dizziness 5 (5.7)
Insomnia 4 (4.6)
Stomach upset/nausea 4 (4.6)
Erythema/flushing 2 (2.3)
Dysarthria 2 (2.3)
Hallucinations 2 (2.3)
Palpitations 2 (2.3)
Chest pain 1 (1.1)
Edema 1 (1.1)
J. Med. Toxicol. (2010) 6:307–310 309Modafinil has been classified as a schedule IV drug by
the Drug Enforcement Administration due to its potential to
cause euphoria and alterations in mood, thought, and
perception. Although a recent review concluded that
modafinil has a low abuse potential [21], a recent volunteer
study demonstrated that modafinil increases dopamine
concentration in the nucleus accumbens area of the brain,
an effect that has been associated with the potential for
abuse [22]. Additionally, reports abound in Internet drug
use forums of modafinil’s misuse among students in order
to facilitate studying and improve grades [23]. In our case
series, one third (11/33) of intentional exposures were due
to abuse or misuse. Given modafinil’s increasingly wide-
spread use, it is likely that cases of toxicity will continue to
be reported to poison control centers.
Our study has several limitations. This was a retrospec-
tive study which limits the amount of data that we were
able to retrieve from each case. Some symptoms may have
been present but were not reported to CPCS, and our
frequency of clinical effects may not represent actual
frequency of effects. It is very likely that our study did
not capture all cases of modafinil toxicity or exposure,
given that reporting of such cases to CPCS is voluntary.
Additionally, it is not possible to confirm exposure in all
cases since assays for measurement of plasma concentra-
tions of modafinil are not widely available.
Effects seen in our series of modafinil exposures were
usually minor, with CNS symptoms and tachycardia most
commonly seen. Clinically significant effects requiring
treatment did occur in a small number of patients. No
significant toxicity occurred with ingestions <400 mg; this
suggests that patients who ingest less than this amount may
be managed safely at home. Additionally, accidental “dou-
ble-dosing” of modafinil was not associated with clinical
effects in the majority of cases, but did result in clinically
significant effects requiring treatment in one patient.
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